# Irena Melnikova

> Irena Melnikova is a Series B investor at Burrill & Company backing Biotechnology and Health Care. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Burrill & Company](https://shizune.co/investors/profile/burrill-co)
- Total investments: 7
- Last investment: Jun 2026
- Lead investor: 57%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/irena-melnikova-b047891

Irena Melnikova is a Series B investor at Burrill & Company focused on Biotechnology and Health Care. Irena Melnikova is the Managing Director at Burrill & Company. She attended UT Health San Antonio.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 57% |
| Health Care | 3 | 43% |
| Medical | 2 | 29% |
| Life Science | 2 | 29% |
| Therapeutics | 2 | 29% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 43% |
| Seed | 1 | 14% |
| Series A | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 43% |
| France | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Flare Therapeutics | Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M | Series C | Jun 30, 2026 |  |
| Oblenio Bio | Oblenio Bio is a biotechnology company that develops T-cell engager therapeutic candidates for autoimmune disease treatment. | $62M | Series B | Jun 25, 2026 |  |
| Oblenio Bio | Oblenio Bio is a biotechnology company that develops T-cell engager therapeutic candidates for autoimmune disease treatment. | $62M | Series B | Jun 25, 2026 |  |
| Crossbow Therapeutics | Crossbow Therapeutics is a seed-stage, stealth-mode oncology startup company. The company develops antibody engineering for intracellular cancer targets. | $77M | Series B | Mar 18, 2026 |  |
| Enodia Therapeutics | Enodia Therapeutics is a biotech company that provides transforming treatments for cancer, inflammation, and viral infection diseases. | $24.2M | Seed | Jan 08, 2026 |  |
| Crossbow Therapeutics | Crossbow Therapeutics is a seed-stage, stealth-mode oncology startup company. The company develops antibody engineering for intracellular cancer targets. | $80M | Series A | Jul 11, 2023 |  |
| Flare Therapeutics | Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $123M | Series B | Mar 22, 2023 |  |

7 of 7 investments shown.

## Co-investors
- [Eli Lilly](https://shizune.co/investors/profile/eli-lilly) — VC Fund, 4 deals together
- [Third Rock Ventures](https://shizune.co/investors/profile/third-rock-ventures) — VC Fund, 4 deals together
- [Aditum Bio](https://shizune.co/investors/profile/aditum-bio) — VC Fund, 2 deals together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 2 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 2 deals together
- [Deep Track Capital](https://shizune.co/investors/profile/deep-track-capital) — VC Fund, 2 deals together

## About Burrill & Company

VC Fund · San Francisco, United States

Burrill & Company is a venture capital and private equity firm that invests in life sciences, biotechnology, and healthcare companies.

5 contacts available at Burrill & Company.

| Name | Title | Profile |
| --- | --- | --- |
| Irena Melnikova | Managing Director | https://shizune.co/investors/profile/irena-melnikova |
| Anna G. Annenko | Business Development Manager | https://shizune.co/investors/profile/anna-g-annenko |
| Ann F. Hanham | Managing Director | https://shizune.co/investors/profile/ann-f-hanham |
| Eduardo Marques de Souza Dantas Matto | Associate | https://shizune.co/investors/profile/eduardo-marques-de-souza-dantas-matto |
| Holly Apgar | Director | https://shizune.co/investors/profile/holly-apgar |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Irena Melnikova invest in?

Irena Melnikova invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Irena Melnikova last invest?

The most recent investment recorded for Irena Melnikova closed in Jun 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co